A 23-Year-Old Woman with Down Syndrome, Type 1 Neurofibromatosis, and Breast Carcinoma [2]

American Journal of Medical Genetics

Volumn 125 A, Issue 1, 2004, Pages 94-96

  Satgé, Daniel ^a   Sasco, Annie J ^b,c   Goldgar, David ^b   Vekemans, Michel ^d   Réthoré, Marie Odile ^e  

^a CENTRE HOSPITALIER   (France)

^b INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^c INSERM   (France)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

^e Ctr Med Jerome Lejeune   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; NEUROFIBROMIN;

ADULT; BREAST CARCINOMA; CANCER RISK; CANCER SUSCEPTIBILITY; CASE REPORT; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE COURSE; DOWN SYNDROME; FEMALE; GENETIC PREDISPOSITION; HUMAN; LETTER; MAMMOGRAPHY; NEUROFIBROMATOSIS; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; TRISOMY 21;

POMACANTHUS MACULOSUS;

EID: 0842305710     PISSN: 15524825     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajmg.a.20429     Document Type: Letter

References (17)

1. Airewele GE, Sigurdson AJ, Wiley KJ, Frieden BE, Caldarera LW, Riccardi VM, Lewis RA, Chintagumpala MM, Ater JL, Plon SE, Bondy ML. 2001. Neoplasms in neurofibromatosis 1 are related to gender but not to family history of cancer. Genet Epidemiol 20:75-86.
2. Brasfield RD, Das Gupta TK. 1972. Von Recklinghausen's disease: A clinicopathological study. Ann Surg 175:86-104.
3. Foos G, Garcia-Ramirez JJ, Galang CK, Hauser CA. 1998. Elevated expression of Ets2 or distinct portions of Ets2 can reverse Ras-mediated cellular tranformation. J Biol Chem 273:18871-18880.
4. Gelmann EP. 1998. Oncogenes in human breast cancer. Chapter 26. In: Bland K, et al. The breast, comprehensive management of benign and malignant diseases, 2 edn. Philadelphia: W.B. Saunders. p 499-517.
5. Hasle H, Clemmensen IH, Mikkelsen M. 2000. Risks of leukaemia and solid tumours in individuals with Down's syndrome. Lancet 355:165-169.
6. Nakamura M, Tangoku A, Kusanagi H, Oka M, Suzuki T. 1998. Breast cancer associated with Recklinghausen's disease: Report of a case. Nippon Geka Hokan (Arch Jpn Chir) 67:3-9.
7. Oesterreich S, Fuqua SAW. 1999. Tumor suppressor genes in breast cancer. Endocrine-Related Cancer 6:405-419.
8. Parkin DM, Whelan SL, Ferlay J, Raymond L, Young J, editors. 1997. Cancer incidence in five continents. Vol. VII. IARC Scientific Publication N 143 IARC Press Lyon, pp 474-505.
9. Rasmussen SA, Yang Q, Friedman JM. 2001. Mortality in neurofibromatosis 1: An analysis using U.S. death certificates. Am J Hum Genet 68:1110-1118.
10. 2-induced apoptosis: Implications for Down's syndrome. Biochem Biophys Res Commun 287:1003-1008.
11. Satgé D, Sommelet D, Geneix A, Nishi M, Malet P, Vekemans M. 1998. A tumor profile in Down syndrome. Am J Med Genet 78:207-216.
12. Satgé D, Sasco AJ, Pujol H, Réthoré M-O. 2001. Les cancers mammaires des femmes trisomiques 21. Bull Acad Natle Med 185:1239-1254.
13. Scholl T, Stein Z, Hansen H. 1982. Leukemia and other cancers, anomalies and infections as causes of death in Down's syndrome in the United States during 1976. Dev Med Child Neurol 24:817-829.
14. Sorensen SA, Mulvihill JJ, Nielsen A. 1986. Long-term follow-up of von Recklinghausen neurofibromatosis. N Engl J Med 314:1010-1015.
15. Weiss B, Bollag G, Shannon K. 1999. Hyperactive Ras as a therapeutic target in neurofibromatosis type 1. Am J Med Genet 89:14-22.
16. Yang Q, Rasmussen SA, Friedman JM. 2002. Mortality associated with Down's syndrome in the USA from 1983 to 1997: A population-based study. Lancet 359:1019-1025.
17. Zöller MET, Rembeck B, Odén A, Samuelsson M, Angervall L. 1997. Malignant and benign tumors in patients with neurofibromatosis type 1 in a defined Swedish population. Cancer 79:2125-2131.